Co-Authors
This is a "connection" page, showing publications co-authored by Philippe Brouqui and Pierre-Edouard Fournier.
Connection Strength
0.497
-
Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis. Int J Antimicrob Agents. 2017 Aug; 50(2):252-254.
Score: 0.180
-
Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant. J Clin Virol. 2021 06; 139:104814.
Score: 0.059
-
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul - Aug; 36:101791.
Score: 0.056
-
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New Microbes New Infect. 2020 Nov; 38:100709.
Score: 0.055
-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May - Jun; 35:101738.
Score: 0.055
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663.
Score: 0.055
-
Respiratory viruses and bacteria among pilgrims during the 2013 Hajj. Emerg Infect Dis. 2014 Nov; 20(11):1821-7.
Score: 0.038